Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Apple Turns 50: From Garage Startup to AI Crossroads 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
SANTA CLARA, Calif., July 13, 2017 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, cardiovascular and metabolic disease research, has released another substantial collection of life science products to its e-commerce platform.
CrownBio will add a significant number of cell lines and reference standards related to EGFR, KRAS, and BRAF signaling cascades of the MAPK pathway, which plays a critical role in the development and progression of cancer. Further enhancements to the CrownBio catalog also include additional monoclonal antibodies to immune checkpoint and cancer-related targets, as well as compounds to activate or inhibit signaling pathways.
This product expansion further strengthens CrownBio’s current product offerings within preclinical drug discovery and cancer research which already includes antibodies for in vivo and in vitro studies, recombinant proteins, recombinant cell lines, tumor samples for oncology research and development, and tumor tissue microarrays.
“The expansion of products validates our commitment to offer a complementary set of reagents, while further broadening the breath of products available from CrownBio. Furthermore, we have extended our customer service hours for more immediate and convenient access to our product support,” commented Debby Saunders, Executive Director of Life Science Development at CrownBio.
“We are very pleased with the growth of the life science division,” stated Laurie Heilmann, SVP of Global Strategy, Marketing and Business Development. “The division continues to demonstrate significant growth, we remain committed to providing products that meet our customers need and a method to access them quickly and easily.”
CrownBio’s online store can be accessed via: https://www.crownbio.com/shop.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries: Jody Barbeau Crown Bioscience Inc. [email protected]
